Country: Malta
Language: English
Source: Medicines Authority
DROSPIRENONE, ETHINYLESTRADIOL
Bayer Public Limited Company 400 South Oak Way, Reading Berkshire RG2 6AD, United Kingdom
G03AA12
DROSPIRENONE 3 mg ETHINYLESTRADIOL 0.03 mg
FILM-COATED TABLET
DROSPIRENONE 3 mg ETHINYLESTRADIOL 0.03 mg
POM
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Withdrawn
2010-07-23
Page 1 of 10 PACKAGE LEAFLET: INFORMATION FOR THE USER Palandra 0.03 mg / 3 mg film-coated tablets Ethinylestradiol / Drospirenone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. _ _ _Keep this leaflet, you may need to read it again. _ _ _ _If you have any further questions, ask your doctor or pharmacist. _ _ _ _This medicine has been prescribed for you, do not pass it on to others. It may harm them. _ _ _ _If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, _ _please tell your doctor or pharmacist_._ _ IN THIS LEAFLET 1. WHAT PALANDRA IS AND WHAT IT IS USED FOR ........................ 2 2. BEFORE YOU TAKE PALANDRA ..................................................... 2 When you should not use Palandra.................................................... 2 When do you need to take special care with Palandra ....................... 3 Palandra and thrombosis ................................................................... 3 Palandra and cancer .......................................................................... 4 Bleeding between periods .................................................................. 5 What you must do if no bleeding occurs in the gap week ................... 5 Palandra and using other medicines .................................................. 5 Laboratory tests ................................................................................. 5 Pregnancy.......................................................................................... 5 Breast-feeding.................................................................................... 5 Driving and using machines ............................................................... 6 Important information about some of the ingr Read the complete document
Page 1 of 16 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Palandra 0.03 mg / 3 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 0.030 mg ethinylestradiol and 3 mg drospirenone Excipient: lactose 46 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Light yellow, round tablet with convex faces, one side embossed with the letters "DO" in a regular hexagon 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oral contraception 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Route of administration: oral use HOW TO TAKE PALANDRA The tablets must be taken every day at about the same time, if necessary with a little liquid, in the order shown on the blister pack. One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval, during which time a withdrawal bleed usually occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started. HOW TO START PALANDRA • No preceding hormonal contraceptive use (in the past month) Tablet-taking has to start on day 1 of the woman’s natural cycle (i.e. the first day of her menstrual bleeding). • Changing from a combined hormonal contraceptive (combined oral contraceptive (COC), vaginal ring, or transdermal patch) The woman should start with Palandra preferably on the day after the last active tablet (the last tablet containing the active substances) of her previous COC, but at the latest on the day following the usual tablet-free or placebo tablet interval of her previous COC. In case a vaginal ring or Page 2 of 16 transdermal patch has been Read the complete document